98%
921
2 minutes
20
Background: Recurrent disease after liver transplant is well recognized for many diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are leading indications for liver transplant, and there is scarce knowledge about recurrence-related end outcomes such as retransplant and mortality. This project aims to assess the proportion of patients transplanted for MASH who develop recurrent disease and adverse clinical outcomes.
Methods: A systematic review and pooled proportions meta-analysis was performed by searching the following databases: MEDLINE, Embase, Scopus, Web of Science Core Collection, and Cochrane Library. Inclusion criteria were studies discussing adult patients with liver transplants secondary to MASH or presumed MASH with recurrent disease-related outcomes. Outcomes were assessed in time frames from <6 mo to ≥5 y.
Results: Of 5859 records, 40 were included (16 157 patients). Recurrent MASLD and MASH (28 studies each) occurred in frequencies of 35%-49% and 11%-24%, respectively. Fibrosis occurred in 4%-25% (13 studies). Recurrent disease-related cirrhosis (13 studies), graft failure (8 studies), and retransplant (9 studies) occurred in 0%-2%, 3%-9%, and 0%-1%, respectively. Recurrent disease-related hepatocellular carcinoma (1 study) and mortality (17 studies) both had a prevalence of 0%. Studies were of moderate or high quality using the Methodological Index for Non-Randomized Studies tool.
Conclusions: Recurrent MASLD and MASH after liver transplant occur frequently, but adverse clinical outcomes due to disease recurrence are infrequent, maybe due to insufficient data on long-term follow-up. Long-term outcomes after transplantation for MASLD appear favorable; however, identifying those more likely to have progressive recurrent disease leading to adverse clinical outcomes may allow for pre- and posttransplant interventions to improve outcomes further.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TP.0000000000005276 | DOI Listing |
Transplantation
September 2025
General Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Background: Mortality after liver transplantation (LT) for hepatocellular carcinoma (HCC) is mainly driven by HCC recurrence. We sought to determine whether post-recurrence survival (PRS) has improved during the last 2 decades.
Methods: Using the Scientific Registry of Transplant Recipients, we included all patients who underwent LT for HCC between 2003 and 2020 and experienced HCC recurrence.
Urol Oncol
September 2025
Department of Urology, Columbia University Irving Medical Center, New York, NY.
Objective: To evaluate the role of Rescue BCG in the treatment of BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC), in order to inform clinical decision-making especially when access to alternative therapies is limited.
Methods: From an institutional database, patients who met the criteria of BCG-unresponsive NMIBC between 2002 and 2023 were identified and sorted into 2 cohorts: those who received additional BCG therapy immediately after BCG-unresponsive designation and those who received alternative treatments such as intravesical chemotherapy and radical cystectomy. Primary endpoint was progression-free survival (PFS).
J Vet Med Sci
September 2025
Laboratory of Veterinary Pathology, School of Veterinary Medicine, Nippon Veterinary and Life Science University.
Information on inflammatory laryngeal masses in dogs remains extremely limited. We aimed to describe the clinical and histopathological features and outcomes of five dogs with bilateral, movable inflammatory laryngeal masses. Stridor was a common clinical sign, followed by dysphonia and snoring, all of which were mild.
View Article and Find Full Text PDFJ Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDFJ Pediatr Surg
September 2025
First Department of Pediatric Surgery, Aristotle University of Thessaloniki, General Hospital "G. Gennimatas", Thessaloniki, Greece.
Background: Thyroid cancer in pediatric patients is distinct from adult-onset thyroid cancer due to differences in disease presentation, management and outcomes. This meta-analysis delves into contemporary data on managing pediatric differentiated thyroid cancer (DTC), assessing outcomes, such as recurrence and mortality, in children with radical total thyroidectomy versus the more conservative lobectomy approach.
Methods: MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), trial registry websites (ClinicalTrials.